# US 2019/0194747 A1 · Nicking and extension amplification reaction (near) of respiratory syncytial virus species

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0194747 A1
- Document ID: US20190194747A1
- Status: Published application
- Kind: A1
- Application number: 16/118,081
- Filed: 2018-08-30
- Published: 2019-06-27
- Earliest claimed: 2017-08-31
- Assignees: Ionian Technologies, Inc.
- Applicants: Ionian Technologies Inc.
- Inventors: Honghua Zhang; Richard Roth
- Web page: https://patentgrep.com/patent/US20190194747A1

## CPC

- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/701: {Specific hybridization probes}
- C12N 2310/11: Antisense
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q 2600/166: Oligonucleotides used as internal standards, controls or normalisation probes
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This invention relates to methods and compositions for detecting the presence or absence of a Respiratory Syncytial Virus target nucleic acid in a biological sample using isothermal nucleic acid amplification.

## Claims

### Claim 1

A composition comprising:
i) a first forward template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of a Respiratory Syncytial Virus (RSV) nonstructural NS2 gene antisense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site; and
ii) a first reverse template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of a RSV nonstructural NS2 gene sense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site; or
iii) a second forward template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of a RSV nucleocapsid gene N antisense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site; and
iv) a second reverse template comprising a nucleic acid sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of a RSV nucleocapsid gene N sense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the recognition region at the 3′ end that is complementary to the 3′ end of the RSV nonstructural NS2 gene antisense strand is 8-30 nucleotides in length, and/or
wherein the recognition region at the 3′ end that is complementary to the 3′ end of the RSV nucleocapsid gene N antisense strand is 8-30 nucleotides in length.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the recognition region at the 3′ end that is complementary to the 3′ end of the RSV nonstructural NS2 gene sense strand is 8-30 nucleotides in length, and/or
wherein the recognition region at the 3′ end that is complementary to the 3′ end of the RSV nucleocapsid gene N sense strand is 8-30 nucleotides in length.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the composition comprising i) and ii) further comprises a probe oligonucleotide comprising a nucleotide sequence complementary to the RSV nonstructural NS2 gene nucleotide sequence.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the composition comprising iii) and iv) further comprises a probe oligonucleotide comprising a nucleotide sequence complementary to the RSV nucleocapsid gene N nucleotide sequence.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the nucleic acid sequence of the first forward template comprises a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 1 (CGACTCACACGAGTCGAAAACTTGATGAAAGA); and
the nucleic acid sequence of the first reverse template comprises a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO 2: (AGACTCCACACGGAGTCTAGTTGACCAGGAATG).

### Claim 7 (depends on 1)

The composition of claim 1, wherein the composition comprising i) and ii) further comprises a probe oligonucleotide comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 3 (ACCAGGAATGTAAATGTGGCCTGGT).

### Claim 8 (depends on 1)

The composition of claim 1, wherein
the nucleic acid sequence of the second forward template comprises a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 6 (GACTCGCACACGAGTCACGTAGTACAGGAGATAA);
the nucleic acid sequence of the second reverse template comprises a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO 7: (GACTCCACACGGAGTCGCTTTTGCACATCATAA).

### Claim 9 (depends on 1)

The composition of claim 1, wherein the composition comprising iii) and iv) further comprises a probe oligonucleotide comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 8 (TGACACATCATAATTGGGAGTGTCA).

### Claim 10 (depends on 1)

The composition of claim 1, further comprising one or more of a DNA polymerase, one or more nicking enzymes, dNTPs or a mixture of dNTPs and ddNTPs.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the DNA polymerase is selected from the group consisting of Geobacillus bogazici DNA polymerase, Bst (large fragment), exo-DNA Polymerase, Manta 1.0 DNA Polymerase (Enzymatics®).

### Claim 12 (depends on 10)

The composition of claim 10, wherein the one or more nicking enzymes are selected from the group consisting of Nt. BspQI, Nb. BbvCi, Nb. BsmI, Nb. BsrDI, Nb. BtsI, Nt. A1wI, Nt. BbvCI, Nt. BstNBI, Nt. CviPII, Nb. Bpu10I, Nt. Bpu10I and N. BspD61.

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition is lyophilized.

### Claim 14 (depends on 4)

The composition of claim 4, wherein the probe is conjugated to a detectable label.

### Claim 15 (depends on 14)

The composition of claim 14, wherein the detectable label is selected from the group consisting of a fluorophore, an enzyme, a quencher, an enzyme inhibitor, a radioactive label, a member of a binding pair, and a combination thereof.

### Claim 16 (depends on 1)

The composition of claim 1, wherein one or more of the first forward template, the first reverse template, the second forward template or the second reverse template comprises one or more modified nucleotides, spacers, or blocking groups.

### Claim 17

A method for the detection of the presence or absence of RSV in a biological sample, wherein the method comprises:
contacting the biological sample with a composition comprising
i) a first forward template comprising a nucleotide sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of a RSV nonstructural NS2 gene antisense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site;
ii) a first reverse template comprising a nucleotide sequence comprising a recognition region at the 3′ end that is complementary to the 3′ end of RSV nonstructural NS2 gene sense strand; a nicking enzyme binding site and a nicking site upstream of the recognition region; and a stabilizing region upstream of the nicking site;
iii) at least one nicking enzyme; and
iv) a DNA polymerase;
amplifying the target nucleotide sequence in a nucleic amplification reaction to provide an amplification product; and
detecting the presence or absence of the amplification product.

### Claim 18 (depends on 17)

The method of claim 17, wherein the at least one nicking enzyme comprises
a first nicking enzyme that is capable of nicking at the nicking site of the first forward template, and does not nick within the RSV nonstructural NS2 gene antisense strand, and/or
a second nicking enzyme that is capable of nicking at the nicking site of the first reverse template and does not nick within the RSV nonstructural NS2 gene sense strand, wherein the first nicking enzyme and the second nicking enzyme may be the same or different.

### Claim 19 (depends on 17)

The method of claim 17, wherein the composition further comprises a probe oligonucleotide comprising a nucleotide sequence complementary to the RSV nonstructural NS2 gene nucleotide sequence.

### Claim 20

A kit comprising:
a template oligonucleotide selected from the group consisting of:
(a) a first forward template comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 1; and
a first reverse template comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO 2; or
(b) a second forward template comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO: 6; and
a second reverse comprising a nucleotide sequence having at least 80%, at least 85% or at least 95% sequence identity to SEQ ID NO 7.
